US 12,435,091 B2
RNA-binding protein multimerization inhibitors and methods of use thereof
Louis B. Nabors, Birmingham, AL (US); Natalia Filippova, Birmingham, AL (US); Xiuhua Yang, Birmingham, AL (US); Subramaniam Ananthan, Birmingham, AL (US); Vibha Pathak, Birmingham, AL (US); and Peter King, Birmingham, AL (US)
Assigned to The UAB Research Foundation, Birmingham, AL (US); Southern Research Institute, Birmingham, AL (US); and The United States Government as Represented by the Department of Veteran Affairs, Washington, DC (US)
Appl. No. 17/996,886
Filed by THE UAB RESEARCH FOUNDATION, Birmingham, AL (US); SOUTHERN RESEARCH INSTITUTE, Birmingham, AL (US); and THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, Washington, DC (US)
PCT Filed Apr. 21, 2021, PCT No. PCT/US2021/028460
§ 371(c)(1), (2) Date Oct. 21, 2022,
PCT Pub. No. WO2021/216757, PCT Pub. Date Oct. 28, 2021.
Claims priority of provisional application 63/013,451, filed on Apr. 21, 2020.
Prior Publication US 2023/0159542 A1, May 25, 2023
Int. Cl. C07D 487/04 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); C07D 519/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61K 45/06 (2013.01); A61P 25/00 (2018.01); A61P 29/00 (2018.01); A61P 35/00 (2018.01); C07D 519/00 (2013.01)] 22 Claims
 
1. A compound of the following formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or prodrug thereof, wherein:
custom character is a single bond or a double bond;
R1, R2, and R3 are each independently selected from the group consisting of hydrogen, halogen, cyano, trifluoromethyl, alkoxy, aryloxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl;
X is NR4R5 or OR4, wherein R4 and R5 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocycloalkyl;
Y1, Y2, and Y3 are each independently selected from NR6 and CR7, wherein R6 and R7 are each independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted carbonyl,
wherein at least two of Y1, Y2, and Y3 are N, and wherein the compound is not:

OG Complex Work Unit Chemistry